Delisting risk
China SXT Pharmaceuticals (SXTC)
Manufacturer of Suxuantang traditional Chinese medicine pieces for Chinese hospitals, wholesalers and pharmacy chains.
$2.28
Pre-market+0.05 (+2.24%)
At close$2.23(−9.35%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Mar 2023 | Q1 FY24Jun 2023 | Q2 FY24Sep 2023 | Q3 FY24Dec 2023 | Q4 FY24Mar 2024 | Q1 FY25Jun 2024 | Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25Mar 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cost of revenue | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2 | 5 | 5 | −3 | 4 | 0 | 0 | 1 | 1 | 6 | 0 | 2 | |
| 2 | 5 | 5 | 4 | 4 | 0 | 0 | 1 | 1 | 6 | 0 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| General & administrative | 2 | 5 | 5 | 4 | 4 | 0 | 0 | 1 | 1 | 6 | 0 | 1 |
| Other expenses | 0 | 0 | 0 | −7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −2 | −5 | −5 | 3 | 0 | 0 | 0 | −1 | −1 | −6 | 0 | −1 |
| 2 | 0 | 5 | −1 | −8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 0 | −5 | 0 | 3 | −8 | 0 | 0 | −1 | −1 | −6 | 0 | −1 |
| Income tax expense | 3 | 0 | 5 | −1 | −11 | 0 | 0 | 0 | 0 | 0 | 0 | −1 |
| Net income from continuing operations | −2 | −5 | −5 | 3 | 3 | 0 | 0 | −1 | −1 | −6 | 0 | 0 |
| Net income | −2 | −5 | −5 | 3 | 3 | 0 | 0 | −1 | −1 | −6 | 0 | 0 |
| EPS, basic | −$5.14 | −$9.67 | −$9.67 | $2.67 | $2.67 | −$0.99 | −$0.99 | −$0.51 | −$0.51 | −$8.23 | $0.14 | $0.14 |
| EPS, diluted | −$5.14 | −$9.67 | −$9.67 | $3.80 | $2.67 | −$0.99 | −$0.99 | −$0.51 | −$0.51 | −$8.23 | $0.14 | $0.14 |
| Weighted average shares, basic | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 |
| Weighted average shares, diluted | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 |
| EBITDA | −2 | −5 | −5 | 4 | 0 | 0 | 0 | −1 | −1 | −6 | 0 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −5 | −5 | 4 | 0 | 0 | 0 | −1 | −1 | −6 | 0 | −1 |